Of note, anti-CD79b-treatment promoted a significant reduction of CNS involvement in both PDX models (P = 0.0302 and P = 0.0098, respectively; Figure 1G–I) indicating that CD79b blockade impacts the engraftment of BCP-ALL cells in vivo and survival of BCP-ALL cells in the CNS. The gene discussed is CD79B; the disease is acute lymphoblastic leukemia.